nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Haemolytic anaemia—Erlotinib—pancreatic cancer	0.039	0.039	CcSEcCtD
Metaxalone—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.0295	0.0295	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Irinotecan—pancreatic cancer	0.026	0.026	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Gemcitabine—pancreatic cancer	0.0253	0.0253	CcSEcCtD
Metaxalone—Abdominal discomfort—Sunitinib—pancreatic cancer	0.0253	0.0253	CcSEcCtD
Metaxalone—Irritability—Fluorouracil—pancreatic cancer	0.023	0.023	CcSEcCtD
Metaxalone—Leukopenia—Tamoxifen—pancreatic cancer	0.0192	0.0192	CcSEcCtD
Metaxalone—Jaundice—Irinotecan—pancreatic cancer	0.0189	0.0189	CcSEcCtD
Metaxalone—Leukopenia—Sunitinib—pancreatic cancer	0.0164	0.0164	CcSEcCtD
Metaxalone—Leukopenia—Irinotecan—pancreatic cancer	0.0135	0.0135	CcSEcCtD
Metaxalone—Leukopenia—Gemcitabine—pancreatic cancer	0.0132	0.0132	CcSEcCtD
Metaxalone—Jaundice—Docetaxel—pancreatic cancer	0.0131	0.0131	CcSEcCtD
Metaxalone—Leukopenia—Fluorouracil—pancreatic cancer	0.013	0.013	CcSEcCtD
Metaxalone—Hypersensitivity—Tamoxifen—pancreatic cancer	0.0129	0.0129	CcSEcCtD
Metaxalone—Pruritus—Tamoxifen—pancreatic cancer	0.0124	0.0124	CcSEcCtD
Metaxalone—Anaphylactic shock—Irinotecan—pancreatic cancer	0.0124	0.0124	CcSEcCtD
Metaxalone—Pruritus—Erlotinib—pancreatic cancer	0.0123	0.0123	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Epirubicin—pancreatic cancer	0.0121	0.0121	CcSEcCtD
Metaxalone—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.012	0.012	CcSEcCtD
Metaxalone—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.0118	0.0118	CcSEcCtD
Metaxalone—Dizziness—Tamoxifen—pancreatic cancer	0.0116	0.0116	CcSEcCtD
Metaxalone—Dizziness—Erlotinib—pancreatic cancer	0.0115	0.0115	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Doxorubicin—pancreatic cancer	0.0112	0.0112	CcSEcCtD
Metaxalone—Vomiting—Tamoxifen—pancreatic cancer	0.0111	0.0111	CcSEcCtD
Metaxalone—Hypersensitivity—Sunitinib—pancreatic cancer	0.011	0.011	CcSEcCtD
Metaxalone—Rash—Tamoxifen—pancreatic cancer	0.011	0.011	CcSEcCtD
Metaxalone—Dermatitis—Tamoxifen—pancreatic cancer	0.011	0.011	CcSEcCtD
Metaxalone—Vomiting—Erlotinib—pancreatic cancer	0.011	0.011	CcSEcCtD
Metaxalone—Somnolence—Irinotecan—pancreatic cancer	0.011	0.011	CcSEcCtD
Metaxalone—Headache—Tamoxifen—pancreatic cancer	0.011	0.011	CcSEcCtD
Metaxalone—Rash—Erlotinib—pancreatic cancer	0.0109	0.0109	CcSEcCtD
Metaxalone—Dermatitis—Erlotinib—pancreatic cancer	0.0109	0.0109	CcSEcCtD
Metaxalone—Headache—Erlotinib—pancreatic cancer	0.0109	0.0109	CcSEcCtD
Metaxalone—Somnolence—Gemcitabine—pancreatic cancer	0.0107	0.0107	CcSEcCtD
Metaxalone—Pruritus—Sunitinib—pancreatic cancer	0.0106	0.0106	CcSEcCtD
Metaxalone—Somnolence—Fluorouracil—pancreatic cancer	0.0105	0.0105	CcSEcCtD
Metaxalone—Nausea—Tamoxifen—pancreatic cancer	0.0104	0.0104	CcSEcCtD
Metaxalone—Nausea—Erlotinib—pancreatic cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Dizziness—Sunitinib—pancreatic cancer	0.00992	0.00992	CcSEcCtD
Metaxalone—Vomiting—Sunitinib—pancreatic cancer	0.00953	0.00953	CcSEcCtD
Metaxalone—Rash—Sunitinib—pancreatic cancer	0.00946	0.00946	CcSEcCtD
Metaxalone—Dermatitis—Sunitinib—pancreatic cancer	0.00945	0.00945	CcSEcCtD
Metaxalone—Headache—Sunitinib—pancreatic cancer	0.00939	0.00939	CcSEcCtD
Metaxalone—Leukopenia—Docetaxel—pancreatic cancer	0.00937	0.00937	CcSEcCtD
Metaxalone—Hypersensitivity—Irinotecan—pancreatic cancer	0.0091	0.0091	CcSEcCtD
Metaxalone—Drowsiness—Epirubicin—pancreatic cancer	0.00903	0.00903	CcSEcCtD
Metaxalone—Nausea—Sunitinib—pancreatic cancer	0.00891	0.00891	CcSEcCtD
Metaxalone—Jaundice—Epirubicin—pancreatic cancer	0.0088	0.0088	CcSEcCtD
Metaxalone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00872	0.00872	CcSEcCtD
Metaxalone—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00854	0.00854	CcSEcCtD
Metaxalone—Pruritus—Gemcitabine—pancreatic cancer	0.00851	0.00851	CcSEcCtD
Metaxalone—Pruritus—Fluorouracil—pancreatic cancer	0.00837	0.00837	CcSEcCtD
Metaxalone—Drowsiness—Doxorubicin—pancreatic cancer	0.00836	0.00836	CcSEcCtD
Metaxalone—Dizziness—Irinotecan—pancreatic cancer	0.00817	0.00817	CcSEcCtD
Metaxalone—Jaundice—Doxorubicin—pancreatic cancer	0.00814	0.00814	CcSEcCtD
Metaxalone—Vomiting—Irinotecan—pancreatic cancer	0.00785	0.00785	CcSEcCtD
Metaxalone—Dizziness—Fluorouracil—pancreatic cancer	0.00782	0.00782	CcSEcCtD
Metaxalone—Rash—Irinotecan—pancreatic cancer	0.00779	0.00779	CcSEcCtD
Metaxalone—Dermatitis—Irinotecan—pancreatic cancer	0.00778	0.00778	CcSEcCtD
Metaxalone—Headache—Irinotecan—pancreatic cancer	0.00774	0.00774	CcSEcCtD
Metaxalone—Vomiting—Gemcitabine—pancreatic cancer	0.00765	0.00765	CcSEcCtD
Metaxalone—Somnolence—Docetaxel—pancreatic cancer	0.00759	0.00759	CcSEcCtD
Metaxalone—Rash—Gemcitabine—pancreatic cancer	0.00759	0.00759	CcSEcCtD
Metaxalone—Dermatitis—Gemcitabine—pancreatic cancer	0.00758	0.00758	CcSEcCtD
Metaxalone—Headache—Gemcitabine—pancreatic cancer	0.00754	0.00754	CcSEcCtD
Metaxalone—Vomiting—Fluorouracil—pancreatic cancer	0.00752	0.00752	CcSEcCtD
Metaxalone—Rash—Fluorouracil—pancreatic cancer	0.00746	0.00746	CcSEcCtD
Metaxalone—Dermatitis—Fluorouracil—pancreatic cancer	0.00745	0.00745	CcSEcCtD
Metaxalone—Headache—Fluorouracil—pancreatic cancer	0.00741	0.00741	CcSEcCtD
Metaxalone—Nausea—Irinotecan—pancreatic cancer	0.00734	0.00734	CcSEcCtD
Metaxalone—Nausea—Gemcitabine—pancreatic cancer	0.00715	0.00715	CcSEcCtD
Metaxalone—Nausea—Fluorouracil—pancreatic cancer	0.00703	0.00703	CcSEcCtD
Metaxalone—Tension—Epirubicin—pancreatic cancer	0.00692	0.00692	CcSEcCtD
Metaxalone—Nervousness—Epirubicin—pancreatic cancer	0.00685	0.00685	CcSEcCtD
Metaxalone—Tension—Doxorubicin—pancreatic cancer	0.00641	0.00641	CcSEcCtD
Metaxalone—Nervousness—Doxorubicin—pancreatic cancer	0.00634	0.00634	CcSEcCtD
Metaxalone—Leukopenia—Epirubicin—pancreatic cancer	0.00632	0.00632	CcSEcCtD
Metaxalone—Hypersensitivity—Docetaxel—pancreatic cancer	0.00629	0.00629	CcSEcCtD
Metaxalone—Pruritus—Docetaxel—pancreatic cancer	0.00604	0.00604	CcSEcCtD
Metaxalone—Leukopenia—Doxorubicin—pancreatic cancer	0.00584	0.00584	CcSEcCtD
Metaxalone—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00576	0.00576	CcSEcCtD
Metaxalone—Dizziness—Docetaxel—pancreatic cancer	0.00565	0.00565	CcSEcCtD
Metaxalone—Vomiting—Docetaxel—pancreatic cancer	0.00543	0.00543	CcSEcCtD
Metaxalone—Rash—Docetaxel—pancreatic cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Dermatitis—Docetaxel—pancreatic cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Headache—Docetaxel—pancreatic cancer	0.00535	0.00535	CcSEcCtD
Metaxalone—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.00533	0.00533	CcSEcCtD
Metaxalone—Somnolence—Epirubicin—pancreatic cancer	0.00512	0.00512	CcSEcCtD
Metaxalone—Nausea—Docetaxel—pancreatic cancer	0.00507	0.00507	CcSEcCtD
Metaxalone—Somnolence—Doxorubicin—pancreatic cancer	0.00474	0.00474	CcSEcCtD
Metaxalone—Hypersensitivity—Epirubicin—pancreatic cancer	0.00424	0.00424	CcSEcCtD
Metaxalone—Pruritus—Epirubicin—pancreatic cancer	0.00407	0.00407	CcSEcCtD
Metaxalone—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00393	0.00393	CcSEcCtD
Metaxalone—Dizziness—Epirubicin—pancreatic cancer	0.00381	0.00381	CcSEcCtD
Metaxalone—Pruritus—Doxorubicin—pancreatic cancer	0.00377	0.00377	CcSEcCtD
Metaxalone—Vomiting—Epirubicin—pancreatic cancer	0.00366	0.00366	CcSEcCtD
Metaxalone—Rash—Epirubicin—pancreatic cancer	0.00363	0.00363	CcSEcCtD
Metaxalone—Dermatitis—Epirubicin—pancreatic cancer	0.00363	0.00363	CcSEcCtD
Metaxalone—Headache—Epirubicin—pancreatic cancer	0.00361	0.00361	CcSEcCtD
Metaxalone—Dizziness—Doxorubicin—pancreatic cancer	0.00352	0.00352	CcSEcCtD
Metaxalone—Nausea—Epirubicin—pancreatic cancer	0.00342	0.00342	CcSEcCtD
Metaxalone—Vomiting—Doxorubicin—pancreatic cancer	0.00339	0.00339	CcSEcCtD
Metaxalone—Rash—Doxorubicin—pancreatic cancer	0.00336	0.00336	CcSEcCtD
Metaxalone—Dermatitis—Doxorubicin—pancreatic cancer	0.00336	0.00336	CcSEcCtD
Metaxalone—Headache—Doxorubicin—pancreatic cancer	0.00334	0.00334	CcSEcCtD
Metaxalone—Nausea—Doxorubicin—pancreatic cancer	0.00317	0.00317	CcSEcCtD
